Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vorapaxar Woes Increase Pressure On Remainder Of Merck CV Pipeline

Executive Summary

The mid-January announcement that Merck & Co. was ending one pivotal trial and removing patients with a history of stroke from another for Phase III anti-clotting agent vorapaxar has called into question the pharma’s continued heavy emphasis on cardiovascular research and development.

You may also be interested in...



For Merck, Outcomes Trials Offer Fast Track To Payers

More so than any other big pharma, Merck is dependent on large outcomes trials. The cost of failure is high, but success would allow entry into massive, highly generic primary care markets with products backed by clinical outcomes data that meet payers’ need for real-world evidence of a drug’s value in terms of health economics as well as clinical efficacy.

Back To The Drawing Board For Portola After Merck Returns Betrixaban

Merck & Co. returned the Phase III-ready oral Factor Xa inhibitor; Portola spins the news as an opportunity, but finding a new partner may be challenging.

Back To The Drawing Board For Portola After Merck Returns Betrixaban

Merck & Co. returned the Phase III-ready oral Factor Xa inhibitor; Portola spins the news as an opportunity, but finding a new partner may be challenging.

Related Content

Topics

UsernamePublicRestriction

Register

PS053069

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel